Liquid Biopsy for Precision Oncology Summit West Coast leaderboard
  • Friday, November 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

SmartLab Exchange Europe 2027 Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 10

KymaThera Raises $80M to Advance PI3Kα Cancer Drug

Oct 7, 2026
KymaThera has raised $80 million in a Series B financing to advance the development of its investigational cancer drug K-1728, an oral PI3Kα inhibitor designed to target multiple…
Read More...

Industry Leaders Explore the Future of RNA Therapeutics Beyond Splicing

Oct 7, 2026
What comes next for RNA-targeted drug discovery? That question will drive several forward-looking discussions at the 9th Annual RNA-Targeted Drug Discovery & Development Summit,…
Read More...

AstraZeneca Opens $1B R&D Centre in Cambridge

Oct 6, 2026
AstraZeneca has opened a new global research and development (R&D) centre in Kendall Square, Cambridge, Massachusetts, as part of a more than $1 billion investment in the state.…
Read More...

Pacira Partners With Molteni to Expand EXPAREL in Europe

Oct 6, 2026
Pacira BioSciences has entered into a strategic partnership with Molteni Farmaceutici to expand access to non-opioid postsurgical pain treatment across several European markets.…
Read More...

Shionogi Plans $2B Acquisition of IntraBio to Expand Rare Disease Portfolio

Oct 5, 2026
Shionogi & Co. has agreed to acquire biopharmaceutical company IntraBio for $2 billion, strengthening its presence in rare diseases and adding an approved treatment for serious…
Read More...

Lilly’s Jaypirca Wins FDA Nod for First-Line CLL Treatment

Oct 5, 2026
Eli Lilly’s Jaypirca (pirtobrutinib) has received an expanded approval from the U.S. Food and Drug Administration (FDA) for certain adults with previously untreated chronic lymphocytic…
Read More...

Lilly’s Foundayo Linked to Lower Long-Term Diabetes and Heart Disease Risk

Oct 5, 2026
Eli Lilly’s oral GLP-1 medicine Foundayo (orforglipron) was associated with significant reductions in predicted long-term risks of type 2 diabetes and cardiovascular disease, according…
Read More...

Sanofi, Regeneron Expand Antibody Collaboration With $8B Deal

Oct 2, 2026
Sanofi and Regeneron Pharmaceuticals are expanding their long-running antibody collaboration to develop four next-generation, long-acting treatments for immune-mediated diseases. The…
Read More...

Abogen, Novartis Sign $7.2B RNA Therapeutics Deal

Oct 2, 2026
Abogen Biosciences has entered into a licensing and option agreement with Novartis to develop RNA-encoded therapies, including a potential new treatment approach for autoimmune…
Read More...

CAS, Novartis Partner on AI-Ready Reaction Data for Drug Discovery

Oct 1, 2026
CAS and Novartis Biomedical Research have entered into a collaboration to improve access to chemical reaction data and support the use of artificial intelligence (AI) in drug discovery.…
Read More...
Previous 1 … 8 9 10 11 12 … 966 Next
Oligonucleotide-based Therapeutics Summit
LEAP HR: Life Sciences Europe
3rd Annual TRP Target Selection & Drug Design Summit
2nd Structure-Based Drug Design Summit San Diego
Liquid Biopsy for Precision Oncology Summit West Coast
2nd Non-Opioid Pain Therapeutics Summit
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Antigen-Specific Immune Tolerance Summit
7th Operationalize Expanded Access Programs Summit
Viral Vector Process Development & Manufacturing Summit
SmartLab Exchange Europe 2027
8th RNAi-Based Therapeutics Summit
17th World ADC London
PFS & Injectable Drug Devices Europe
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Biomarker Operations & Biospecimen Management
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • OBI Pharma Signs $2 Billion ADC Deal with Novartis
  • Erasca and Bristol Myers Squibb Partner on Pancreatic Cancer Treatment
  • GSK Wins FDA Approval for Nelkarmi in Advanced Lung Cancer
  • OXB Partners with Aura Biosciences for Phase 3 Cancer Drug Development
  • Skylark Bio Advances Hearing Loss Gene Therapy to Younger Children

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Cell Therapy Safety in Autoimmune Disease

7th Operationalize: Expanded Access Programs Summit East…

As AI and ICH M15 Transform Drug Development, Industry…

Industry Leaders Explore the Future of RNA Therapeutics…

Direct RNA Binding Emerges as a Powerful Approach for…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.